 |
Current, pipeline and emerging drugs for the treatment of peripheral
neuropathy and neuropathic pain This report estimates that Peripheral
Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270 million
individuals globally. PN and NP are causally linked to a number of diseases,
however diabetes, cancer and HIV alone are expected to increase the
prevalence of PN and NP by more than 10% by 2012. PN and NP are areas of
significant and critical unmet need. There are no cures for PN and NP is
difficult to treat and often unresponsive to all available therapies.
Today's armoury of drugs for the treatment of NP shows significant reliance
on "second-indication" drugs, which were initially developed to treat other
primary indications (e.g. anticonvulsants, antidepressants). This report
gives a comprehensive update on all current drugs, together with the entire
drug development pipeline, from pre-clinical through to Phase III,
Registration and initial Launch. The pipeline includes 80 candidates being
developed to treat PN and NP as a primary indication and 60
"second-indication" drugs. More than 300 patents published in the PN and NP
field between 2002 and 2007 have also been assessed and presented, together
with the identification of potential candidate molecules and drug targets
which have not entered the development pipeline, but which may do so in the
future. This report was written to provide a comprehensive update on
therapeutic developments relating to PN and NP, both in tackling its most
serious and debilitating symptoms, but also in targeting and potentially
correcting the underlying disease mechanisms. Commercial evaluation and
assessments including markets, market size, market sectors, sales and trends
relating to PN and NP are also included in this report.
|
